Summit Therapeutics (SMMT) grants director stock options and fees

Rhea-AI Filing Summary

Summit Therapeutics Inc. reported that director Alessandra Cesano received new stock option awards. On 01/02/2026, she was granted a stock option for 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on 01/02/2036. These shares vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the grant year, as long as she continues serving as a non-salaried director.

She was also granted a separate stock option for 3,219 shares of common stock at the same $17.52 exercise price, expiring on 01/02/2036. This option was issued under the company’s Director Retainer Option Election Plan in lieu of cash retainer fees of $28,200 and vests in four quarterly installments on March 31, June 30, September 30 and December 31 following her election, contingent on continued board service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cesano Alessandra

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$17.52	01/02/2026		A		35,000		(1)	01/02/2036	Common Stock	35,000	(2)	35,000	D
Stock Option (right to buy)	$17.52	01/02/2026		A		3,219		(3)	01/02/2036	Common Stock	3,219	$8.76(4)	3,219	D

Explanation of Responses:

1. The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.

2. Not applicable.

3. The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.

4. The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $28,200.

Remarks:

	/s/ Bhaskar Anand, as Attorney-in-Fact for Alessandra Cesano	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Summit Therapeutics (SMMT) report for Alessandra Cesano?

The company reported that director Alessandra Cesano received two stock option grants on 01/02/2026, both giving her the right to buy Summit Therapeutics common stock in the future.

How many Summit Therapeutics stock options were granted to the director in this Form 4?

She received one option covering 35,000 shares of common stock and another option covering 3,219 shares, for a total of 38,219 optioned shares.

What is the exercise price and expiration date of the new Summit Therapeutics options?

Both stock option grants have an exercise price of $17.52 per share and an expiration date of 01/02/2036, giving long-dated rights to purchase shares.

How do the Summit Therapeutics director stock options vest for Alessandra Cesano?

The 35,000-share option vests in four quarterly installments on March 31, June 30, September 30 and December 31 of the grant year, while the 3,219-share option vests in four quarterly installments on the same quarter-end dates following her election, in each case requiring that she remain a non-salaried director on each vesting date.

Why did Summit Therapeutics grant a 3,219-share option to the director?

The 3,219-share stock option was issued under the issuer’s Director Retainer Option Election Plan in lieu of cash retainer fees of $28,200, effectively paying part of her board compensation in equity.

Is this Summit Therapeutics Form 4 about stock purchases or option grants?

This Form 4 discloses stock option grants, not open-market share purchases. The director received options with a set exercise price, which may be exercised for shares in the future if they vest.